Targets › TNFRSF17
25 programs from 22 companies in 174 trials: 77 Phase 2, 63 Phase 1, 30 Phase 3, 4 Phase 4; Oncology, Immunology, Metabolic and endocrine; next expected readout Dec 2026.
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. (UniProt, Q02223)
Open in Phaseline: the race on TNFRSF17, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johnson & Johnson (Janssen) | Ciltacabtagene Autoleucel (JNJ-68284528) Tumor necrosis factor receptor superfamily member 17 binding agent | TNFRSF17 | Phase 4 | Multiple Myeloma; Recurrent Multiple Myeloma; High Risk Smoldering Multiple Myeloma; Relapse Multiple Myeloma … | Feb 2027 |
| Pfizer | Elranatamab T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent | CD3E, CD3G, CD3D, TNFRSF17 | Phase 4 | Multiple Myeloma; Multiple Myeloma, Newly Diagnosed; Relapsed Refractory Multiple Myeloma (RRMM); Refractory Multiple Myeloma … | May 2027 |
| Regeneron Pharmaceuticals | Linvoseltamab anti-B-cell maturation antigen x anti-CD3 bispecific antibody | BCMA, GPRC5D, CD3E, TNFRSF17 | Phase 4 | Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) … | Aug 2027 |
| GSK | Belantamab mafodotin Tumor necrosis factor receptor superfamily member 17 binding agent; Tubulin inhibitor | TNFRSF17, Tubulin | Phase 3 | Multiple Myeloma; Amyloidosis; Plasma Cell Myeloma; Myeloma Multiple … | Dec 2026 |
| Johnson & Johnson (Janssen) | Teclistamab T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent | CD3E, CD3G, CD3D, TNFRSF17 | Phase 3 | Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) … | Apr 2027 |
| Johnson & Johnson (Janssen) | JNJ-79635322 Bispecific antibody targeting CD3 and BCMA | CD3E, TNFRSF17 | Phase 3 | Multiple Myeloma; Relapsed or Refractory Multiple Myeloma | Apr 2027 |
| Johnson & Johnson (Janssen) | Ramantamig BCMAxGPRC5DxCD3 trispecific antibody | TNFRSF17, CD3E, BCMA, GPRC5D | Phase 3 | Multiple Myeloma | Dec 2027 |
| Bristol-Myers Squibb | idecabtagene vicleucel Tumor necrosis factor receptor superfamily member 17 binding agent | TNFRSF17 | Phase 3 | Multiple Myeloma | Nov 2029 |
| Keymed Biosciences Co.Ltd | CM336 BCMA/CD3 bispecific antibody | BCMA, CD3E, TNFRSF17 | Phase 2 | Primary Light-Chain Amyloidosis; Multiple Myeloma; Autoimmune Cytopenia; Autoimmune Bullous Disease | Dec 2026 |
| Peking University First Hospital | 68Ga-BCMA BCMA-targeted PET imaging agent | TNFRSF17 | Phase 2 | Multiple Myeloma | Dec 2027 |
| Peking University People's Hospital | BCMA-CD19 CAR-T therapy Dual-targeted CAR-T cell therapy against BCMA and CD19 | TNFRSF17, CD19 | Phase 2 | Systemic Lupus Erythematosus | Dec 2027 |
| iCell Gene Therapeutics | ICG318 BCMA-CD19 dual-targeting CAR-T cells with IL-15/IL-15 sushi domain | TNFRSF17, CD19, BCMA | Phase 2 | Systemic Lupus Erythematosus (SLE); Inflammatory Myopathy | Dec 2027 |
| PETHEMA Foundation | Anitocabtagene Autoleucel CAR-T cell therapy targeting BCMA | TNFRSF17 | Phase 2 | De Novo Multiple Myeloma | Mar 2028 |
| The First Hospital of Jilin University | IL-15-armored BCMA-targeted CAR-T cells IL-15-armored CAR-T cells targeting BCMA | TNFRSF17, IL15 | Phase 2 | Relapsed/Refractory Multiple Myeloma | Jul 2028 |
| Memorial Sloan Kettering Cancer Center | Elranatamab-bcmm Bispecific antibody targeting BCMA and CD3 | TNFRSF17, CD3E | Phase 2 | Multiple Myeloma | Aug 2029 |
| Multiple Myeloma Research Consortium | Linvoseltamab B-cell maturation antigen (BCMA) × CD3 bispecific monoclonal antibody | TNFRSF17, CD3E | Phase 2 | High Risk Newly Diagnosed Multiple Myeloma | Oct 2035 |
| The First Affiliated Hospital of Soochow University | CART-138/BCMA/19/more Multi-antigen CAR-T cell therapy targeting CD138, BCMA (TNFRSF17), CD19, and additional an | CD138, TNFRSF17, CD19 | Phase 1 | Multiple Myeloma | Dec 2026 |
| Gracell Biotechnologies (Shanghai) | GC012F BCMA/CD19 dual CAR-T cell therapy | TNFRSF17, CD19, BCMA | Phase 1 | Multiple Myeloma; Refractory Systemic Lupus Erythematosus; Relapsed/Refractory AL Amyloidosis | Feb 2027 |
| Beijing Biotech | Autologous anti-BCMA CAR-T cells CAR-T cell therapy targeting BCMA-expressing plasma cells | TNFRSF17 | Phase 1 | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS | Mar 2027 |
| Technische Universität Dresden | MDC-CAR-BCMA001 BCMA-targeting CAR T-cell therapy | TNFRSF17 | Phase 1 | Neoplasms | Jun 2027 |
| Vyriad | VV169 In vivo BCMA-CAR T cell therapy (T-cell targeted lentiviral vector expressing BCMA-directe | TNFRSF17 | Phase 1 | Multiple Myeloma Refractory | Aug 2027 |
| David Avigan | BCMA CAR-T Anti-BCMA CAR-T cell therapy | TNFRSF17 | Phase 1 | Multiple Myeloma | Mar 2028 |
| Medical College of Wisconsin | BCMA-TGFβ CAR-T cells BCMA-targeted CAR-T cell therapy with TGF-beta costimulatory domain | TNFRSF17 | Phase 1 | Multiple Myeloma | May 2028 |
| Chongqing Precision Biotech | BCMA/CD70 CAR-T cells Dual-targeted CAR-T cell therapy against BCMA and CD70 | TNFRSF17, CD70 | Phase 1 | Systemic Lupus Erythematosus | Aug 2028 |
| AstraZeneca | AZD4045 Allogeneic CAR-T cell therapy targeting BCMA (B cell maturation antigen) | TNFRSF17 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Mar 2031 |
Multiple Myeloma (96) Recurrent Multiple Myeloma (6) Relapsed Refractory Multiple Myeloma (RRMM) (5) AL Amyloidosis (5) Relapsed/Refractory Multiple Myeloma (4) Multiple Myeloma, Newly Diagnosed (3) Myeloma (3) Multiple Myeloma (MM) (3) Relapsed or Refractory Multiple Myeloma (2) Relapse Multiple Myeloma (2) Refractory Multiple Myeloma (2) Plasma Cell Myeloma (2)
mixed (13), other (6), protein or peptide (3), antibody (1), small molecule (1)
Johnson & Johnson (Janssen) (4) Regeneron Pharmaceuticals (1) AstraZeneca (1) David Avigan (1) Pfizer (1) GSK (1) Peking University People's Hospital (1) Gracell Biotechnologies (Shanghai) (1) Technische Universität Dresden (1) Bristol-Myers Squibb (1) Keymed Biosciences Co.Ltd (1) The First Hospital of Jilin University (1) The First Affiliated Hospital of Soochow University (1) Medical College of Wisconsin (1) Chongqing Precision Biotech (1) iCell Gene Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) Peking University First Hospital (1) Multiple Myeloma Research Consortium (1) Beijing Biotech (1)
CD3E (8) BCMA (5) CD19 (4) GPRC5D (2) CD3G (2) CD3D (2) Tubulin (1) IL15 (1) CD138 (1) CD70 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.